DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0002298 A1 MULLER Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0002298 A1 MULLER Et Al US 2016.0002298A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0002298 A1 MULLER et al. (43) Pub. Date: Jan. 7, 2016 (54) AMATOXIN DERIVATIVES (30) Foreign Application Priority Data (71) Applicant: HEIDELBERG PHARMA GMBH, Mar. 4, 2013 (EP) .................................. 13OO 1074.7 Ladenburg (DE) Publication Classification (72) Inventors: Christoph MULLER, Birkenau (DE); (51) Int. Cl Jan ANDERL, Modautal (DE); Werner cok /64 (2006.01) LUTZ, Weinheim (DE): Torsten C07K 16/32 (2006.01) HECHLER, Bensheim (DE) (52) U.S. C. CPC. C07K 7/64 (2013.01); C07K 16/32 (2013.01); A61K47/48569 (2013.01); A61K 47/48492 (73) Assignee: HEIDELBERG PHARMA GMBH, (2013.01) Ladenburg (DE) (57) ABSTRACT (21) Appl. No.: 14/769,970 The invention relates to tumour therapy. In one aspect, the 1-1. present invention relates to conjugates of an amatoxin and a (22) PCT Filed: Mar. 10, 2014 target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other (86). PCT No.: PCT/EP2014/OOO614 disorders and diseases. In a further aspect the invention S371 (c)(1), relates to pharmaceutical compositions comprising Such con (2) Date: Aug. 24, 2015 jugates. O R R2 R R O-amanitin OH OH NH2 OH 3-amanitin OH OH OH OH Y-amanitin H OH NH2 OH e-amanitin H OH OH OH amanin OH OH OH H amaninamide OH OH NH2 H amanulin H H NH2 OH amanullinic acid H H OH OH Patent Application Publication Jan. 7, 2016 Sheet 1 of 7 US 2016/0002298 A1 Fig. 1 O-amanitin OH NH2 OH 3-amanitin OH OH OH V-amanitin OH NH2 OH 8-amanitin OH OH OH amanin OH OH OH amaninamide OH OH NH2 amanullin NH2 OH amanullinic acid OH OH Patent Application Publication Jan. 7, 2016 Sheet 2 of 7 US 2016/0002298 A1 Fig. 2 SKOV-3 120 110 100 10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 Concentration M Her-30.0643 (4.4 O Her-30.10333.9 v Her-30.1036 (4.0) Her-30.0643 (4.4). Her-30.1033 (3.9 Her-30.1036 (4.0) EC50 2.942e-O 11 2.748e-011 3.832e-O 11 Patent Application Publication Jan. 7, 2016 Sheet 3 of 7 US 2016/0002298 A1 Fig. 3 SKOV-3 120 110 100 10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 Concentration M Her-30.0643 (4.3) O Her-30.1165 (5.0) Her-30.0643 (4.3) Her-30.1165 (5.0) EC50 2.713e-011 1,081 e-010 Patent Application Publication Jan. 7, 2016 Sheet 4 of 7 US 2016/0002298 A1 Fig. 4 SKBR-3 120 110 100 10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 Concentration (M) Her-30.0643 (4.4) • Her-30.10333.9 v Her-30.1036 (4.0) Her-30.0643 (4.4). Her-30.1033 (3.9 Her-30.1036 (4.0) EC50 1997e-011 1258e-011 3.271e-011 Patent Application Publication Jan. 7, 2016 Sheet 5 of 7 US 2016/0002298 A1 Fig. 5 UIMT-1 120 110 100 i 10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 Concentration M Her-30.0643 (4.4 o Her-30.1033 (3.9 v Her-30.1036 (4.0) Her-30.0643 (4.4). Her-30.1033 (3.9 Her-30.1036 (4.0) EC50 1004e-009 7.912e-010 2.1.03e-009 Patent Application Publication Jan. 7, 2016 Sheet 6 of 7 US 2016/0002298 A1 Fig. 6 400 3SOa. 300 25 O 2 O 150 10-is SO single dose i.v. w8- PBS. were 30pug/kg Her-30.0643 -0-150 g/kg Her-30.0643 co 30g/kg. Her-30.1036 -- 150 g/kg Her-30.1036 Patent Application Publication Jan. 7, 2016 Sheet 7 of 7 US 2016/0002298 A1 Fig. 7 day 9, all animals dead 0 1 2 3 4 5 S 8 9, 10 1 12 13 14 15 Day -- PBS -0-300g/kg her-30.0643 --300g/kg Her-30.1036 US 2016/0002298 A1 Jan. 7, 2016 AMATOXIN DERVATIVES of these conjugates on the proliferation of breast cancer cells (cell line MCF-7), pancreatic carcinoma (cell line Capan-1), FIELD OF THE INVENTION colon cancer (cell line Colo205), and cholangiocarcinoma 0001. The invention relates to tumour therapy. In one (cell line OZ) were shown. aspect, the present invention relates to conjugates of an ama 0006 Structure activity relationship of amatoxins is toxin and a target-binding moiety, e.g. an antibody, connected reviewed in by Wieland (T. Wieland, Peptides of Poisonous by certain linkages, which are useful in the treatment of Amanita Mushrooms, Springer series in molecular biology, cancer and other disorders and diseases. Inafurther aspect the Springer Verlag New York, 1986). The hydroxyl group of invention relates to pharmaceutical compositions comprising amino acid 2 (hydroxy proline) and the Y-hydroxy group of Such conjugates. amino acid3 (dihydroxy-isoleucine) are assumed as essential for activity, whereas the functionalities at amino acid 1 (as BACKGROUND OF THE INVENTION partate or asparagine), amino acid 4 (6-hydroxy-tryptophan) 0002 Amatoxins are cyclic peptides composed of 8 amino and the 8-hydroxy-group at amino acid 3 are more tolerant for acids. They can, for example, be isolated from Amanita phal chemical modifications. This indicates that the latter posi loides mushrooms or prepared synthetically. Amatoxins spe tions are the preferred sites for linker attachment, while modi cifically inhibit the DNA-dependent RNA polymerase II of fications of the first ones should be avoided. mammalian cells, and thereby also the transcription and pro 0007. It is known that amatoxins are relatively non-toxic tein biosynthesis of the affected cells. Inhibition of transcrip when coupled to large biomolecule carriers. Such as antibody tion in a cell causes stop of growth and proliferation. Though molecules, and that they exert their cytotoxic activity only not covalently bound, the complex between amanitin and after the biomolecule carrier is cleaved off. In light of the RNA polymerase II is very tight (K, 3 nM). Dissociation of toxicity of amatoxins, particularly for liver cells, it is of out amanitin from the enzyme is a very slow process, thus making most importance that amatoxin conjugates for targeted recovery of an affected cell unlikely. When the inhibition of tumour therapy remain highly stable after administration in transcription lasts too long, the cell will undergo programmed plasma, and that the release of the amatoxin occurs after internalization in the target cells. In this context, minor cell death (apoptosis). improvements of the conjugate stability may have drastic 0003. The use of amatoxins as cytotoxic moieties for tumour therapy had already been explored in 1981 by cou consequences for the therapeutic window and the safety of the pling an anti-Thy 1.2 antibody to C-amanitin using a linker amatoxin conjugates for therapeutic approaches. attached to the indole ring of Trp (amino acid 4: see FIG. 1) OBJECTS OF THE INVENTION via diazotation (Davis & Preston, Science 1981, 213, 1385 1388). Davis & Preston identified the site of attachment as 0008. It was an object of the present invention to provide position 7". Morris & Venton demonstrated as well that sub further target-binding moiety amatoxin conjugates that are stitution at position 7" results in a derivative, which maintains stable in plasma, so that harmful side effects to non-target cytotoxic activity (Morris & Venton, Int. J. Peptide Protein cells are minimized. Res 1983, 21419-430). 0004 Patent application EP 1859811A1 (published Nov. SUMMARY OF THE INVENTION 28, 2007) described conjugates, in which the Y C-atom of 0009. The present invention is based on the unexpected amatoxin amino acid 1 of B-amanitin was directly coupled, observation that a ring formation via the two oxygen atoms i.e. without a linker structure, to albumin or to monoclonal bound to they and the ÖC atoms of amatoxinamino acid3 can antibody HEA125, OKT3, or PA-1. Furthermore, the inhibi improve the tolerability of target-binding moiety amatoxin tory effect of these conjugates on the proliferation of breast conjugates without interfering with the interaction of Such cancer cells (MCF-7), Burkitt's lymphoma cells (Raji), and amatoxins with their target, the DNA-dependent RNA poly T-lymphoma cells (Jurkat) was shown. The use of linkers was merase II of mammalian cells. To date, the presence of the Suggested, including linkers comprising elements such as hydroxyl group bound to the YC atom of amatoxinamino acid amide, ester, ether, thioether, disulfide, urea, thiourea, hydro 3 has been considered essential for the efficacy of amatoxins carbon moieties and the like, but no such constructs were and amatoxin conjugates. Wieland (T. Wieland, Peptides of actually shown, and no more details, such as attachment sites Poisonous Amanita Mushrooms, Springer Series in Molecu on the Amatoxins, were provided. lar Biology, Springer Verlag New York, 1986: Wieland T. 0005 Patent applications WO 2010/115629 and WO Rempel D, Gebert U, Buku A, Boehringer H. Uber die 2010/115630 (both published Oct. 14, 2010) describe conju Inhaltsstoffe des grinen Knollenblatterpilzes. XXXII. Chro gates, where antibodies, such as anti-EpCAM antibodies Such matographische Auftrennung der Gesamtgifte und Isolierung as humanized huHEA125, are coupled to amatoxins via (i) der neuen Nebentoxine Amanin und Phallisin sowie des the YC-atom of amatoxin amino acid 1, (ii) the 6' C-atom of ungiftigen Amanullins. Liebigs Ann Chem.
Load more

Recommended publications
  • Meeting Key Synthetic Challenges in Amanitin Synthesis with a New Cytotoxic Analog: 50-Hydroxy- Cite This: Chem
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Meeting key synthetic challenges in amanitin synthesis with a new cytotoxic analog: 50-hydroxy- Cite this: Chem. Sci., 2020, 11, 11927 0 † All publication charges for this article 6 -deoxy-amanitin have been paid for by the Royal Society of Chemistry Alla Pryyma, Kaveh Matinkhoo, Antonio A. W. L. Wong and David M. Perrin * Appreciating the need to access synthetic analogs of amanitin, here we report the synthesis of 50-hydroxy- Received 29th July 2020 60-deoxy-amanitin, a novel, rationally-designed bioactive analog and constitutional isomer of a-amanitin, Accepted 2nd October 2020 that is anticipated to be used as a payload for antibody drug conjugates. In completing this synthesis, we DOI: 10.1039/d0sc04150e meet the challenge of diastereoselective sulfoxidation by presenting two high-yielding and rsc.li/chemical-science diastereoselective sulfoxidation approaches to afford the more toxic (R)-sulfoxide. drug-tolerant cell subpopulations.7 Examples include ADCs for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction targeting human epidermal growth factor receptor 2 and pros- 8 9 a-Amanitin, the deadliest of the amatoxins produced by the tate specic membrane antigen. With but a few exceptions, death-cap mushroom Amanita phalloides, is a potent, orally nearly all bioconjugates to a cytotoxic amanitin have emerged 1 a available inhibitor of RNA polymerase II (pol II) (Ki 10 nM), from naturally-sourced -amanitin. To date, conjugation that has been validated as a payload for targeted cancer handles used for a-amanitin-based bioconjugates include the d- 2a therapy.2 First described in 1907 3 and isolated in 1941,4 a- hydroxyl of (2S,3R,4R)-4,5-dihydroxyisoleucine (DHIle), the 10 0 amanitin is a compact bicyclic octapeptide that has been asparagine side chain, and the 6 -hydroxyl of the tryptathio- 11 indispensable for probing RNA pol II-catalysed transcription in nine staple.
    [Show full text]
  • WSC 2000-01 Conference 1
    The Armed Forces Institute of Pathology Department of Veterinary Pathology WEDNESDAY SLIDE CONFERENCE 2002-2003 CONFERENCE 17 12 February 2003 Conference Moderator: LTC Gary Zaucha, DVM Diplomate, ACVP, ABT, and ACVPM Chief, Department of Comparative Pathology Walter Reed Army Institute of Research Silver Spring, MD 20910 CASE I – 1614-1 (AFIP 2850109) Signalment: 5-month-old outbred female Swiss-Webster mouse History: Sentinel mouse in a laboratory colony housed on dirty bedding from other mouse cages, part of an infectious disease surveillance program. Euthanized due to lethargy and unthriftiness. Gross Pathology: Stomach distended approximately three times by gas, fluid, and partially digested food. Kidneys shrunken, pale, and pitted. Multifocal hemorrhagic necrosis and thrombosis of the ovaries bilaterally. Laboratory Results: Negative for all murine infectious pathogens tested in the colony surveillance program by serology, respiratory and intestinal cultures, fecal examination, anal tape, and skin scrapings. Contributor’s Morphologic Diagnosis: Kidney: Chronic nephropathy characterized by membranous glomerulopathy, lymphoplasmacytic adventitial vasculitis and perivasculitis, tubular degeneration, ectasia, and regeneration with protein, hemoglobin, cellular, waxy, and granular casts, and lymphoplasmacytic and histiocytic interstitial nephritis, severe. Contributor’s Comment: This case is consistent with the previously reported syndrome of gastric dilatation and chronic nephropathy in mice exposed to dirty bedding [1]. Although the mean age of affected mice in the published report was 10 months, similar lesions are sometimes found in animals as young as 3 or 4 months of age. The kidney disease appears immune-mediated and is presumably the result of chronic high antigen exposure, although there may be more than one inciting process.
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center
    Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Sep 03; 8(E):616-622. https://doi.org/10.3889/oamjms.2020.4208 eISSN: 1857-9655 Category: E - Public Health Section: Public Health Disease Control A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center Leonardo Pennisi1, Anna Lepore1, Roberto Gagliano-Candela2*, Luigi Santacroce3, Ioannis Alexandros Charitos1 1Department of Emergency/Urgent, National Poison Center, Azienda Ospedaliero Universitaria Ospedali Riuniti, Foggia, Italy; 2Department of Interdisciplinary Medicine, Forensic Medicine, University of Bari, Bari, Italy; 3Ionian Department, Microbiology and Virology Lab, University of Bari, Bari, Italy Abstract Edited by: Sasho Stoleski BACKGROUND: The “Ospedali Riuniti’s Poison Center” (Foggia, Italy) provides a 24 h telephone consultation in Citation: Pennisi L, Lepore A, Gagliano-Candela R, Santacroce L, Charitos IA. A Report on Mushrooms clinical toxicology to the general public and health-care professionals, including drug information and assessment of Poisonings in 2018 at the Apulian Regional Poison Center. the effects of commercial and industrial chemical substances, toxins but also plants and mushrooms. It participates Open Access Maced J Med Sci. 2020 Sep 03; 8(E):616-622. in diagnosis and treatment of the exposure to toxins and toxicants, also throughout its ambulatory activity. https://doi.org/10.3889/oamjms.2020.4208 Keywords: Poisoning; Intoxication; Epidemiology; Poison center; Mushroom poisoning METHODS: To report data on the epidemiology of mushroom poisoning in people contacting our Poison Center we *Correspondence: Roberto Gagliano-Candela, made computerized queries and descriptive analyses of the medical records database of the mushroom poisoning Department of Interdisciplinary Medicine, Forensic in the poison center of Foggia from January 2018 to December 2018.
    [Show full text]
  • Conference 1 C O N F E R E N C E 16 29 January 2020 18 August, 2021 Dr
    Joint Pathology CeJointnter Pathology Center Veterinary PatholVeterinaryogy Service Pathologys Services WEDNESDAY SLIDE CONFERENCE 2021-2022 WEDNESDAY SLIDE CONFER ENCE 2019-2020 Conference 1 C o n f e r e n c e 16 29 January 2020 18 August, 2021 Dr. Ingeborg Langohr, DVM, PhD, DACVP Professor Department of Pathobiological Sciences Louisiana S tate University School of Veterinary Medicine Baton RouJointge, L APathology Center Silver Spring, Maryland CASE I: CASE S1809996 1: 1 ((4152313JPC 4135077-00) ). Microscoptan/purple.ic Descr ipThetio n:medullary The inte rstitparenchymaium was within thedisrupted section isby diff dozensusel yof infilt brightra tedred btoy dull purple SignalmeSignalment:nt: A 3-mont h-old, male, mixed- moderate linesto lar thatge radiatednumbers from of pre thedomi levelna ofntl they renal crest breed pig 6(-Susmonth scrofa-old )male (intact) mastiff (Canis mononuclethroughar cell thes a lonmedulla.g with edema. There familiaris). is abunda nt type II pneumocyte hyperplasia History: This pig had no previous signs of lining alveolar septae and many of the illness, andHistory: was found dead. The patient was referred to a veterinary medicalalveola r spaces have central areas of Gross Patholteachingogy : hospitalApprox imfollowingately 70% an o facute, 1-dayne- crotic macrophages admixed with other the lungs,history primar ofily lethargy in the c andrani ainappetencel regions o fthat quicklymononucle ar cells and fewer neutrophils. the lobes, progressedwere patch toy obtundation. dark red, and Bloodwork firm performedOc casionally there is free nuclear basophilic comparedat to thethe rDVMmore norevealedrmal ar etooas ofhigh lun tog. read ALT, elevated ALP (805 U/L), hypoalbuminemia (2.7 Laboratorg/dL)y re suandlts: hypoglycemia Porcine reprodu (23 cmg/dL).tive PT and and respiraaPTTtory weresyndrome both prolonged (PRRS) PCat >100R wa secs and >300 positive frsec,om sprespectively.lenic tissue, Protein and P RandRS IHCbilirubin were was strongdetectedly immunore on a urineactive dipstick.
    [Show full text]
  • Poisonous Mushrooms; a Review of the Most Common Intoxications A
    Nutr Hosp. 2012;27(2):402-408 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Poisonous mushrooms; a review of the most common intoxications A. D. L. Lima1, R. Costa Fortes2, M. R.C. Garbi Novaes3 and S. Percário4 1Laboratory of Experimental Surgery. University of Brasilia-DF. Brazil/Paulista University-DF. Brazil. 2Science and Education School Sena Aires-GO/University of Brasilia-DF/Paulista University-DF. Brazil. 3School of Medicine. Institute of Health Science (ESCS/FEPECS/SESDF)/University of Brasilia-DF. Brazil. 4Institute of Biological Sciences. Federal University of Pará. Brazil. Abstract HONGOS VENENOSOS; UNA REVISIÓN DE LAS INTOXICACIONES MÁS COMUNES Mushrooms have been used as components of human diet and many ancient documents written in oriental coun- Resumen tries have already described the medicinal properties of fungal species. Some mushrooms are known because of Las setas se han utilizado como componentes de la their nutritional and therapeutical properties and all over dieta humana y muchos documentos antiguos escritos en the world some species are known because of their toxicity los países orientales se han descrito ya las propiedades that causes fatal accidents every year mainly due to medicinales de las especies de hongos. Algunos hongos misidentification. Many different substances belonging to son conocidos por sus propiedades nutricionales y tera- poisonous mushrooms were already identified and are péuticas y de todo el mundo, algunas especies son conoci- related with different symptoms and signs. Carcino- das debido a su toxicidad que causa accidentes mortales genicity, alterations in respiratory and cardiac rates, cada año, principalmente debido a errores de identifica- renal failure, rhabidomyolisis and other effects were ción.
    [Show full text]
  • AMATOXINS in EDIBLE MUSHROOMS H. FAULSTICH* And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 64, number I FEBS LETTERS April 1976 AMATOXINS IN EDIBLE MUSHROOMS H. FAULSTICH* and M. COCHET-MEILHAC** Max-Planck-Institut fiir medizinische Forschungp Abteilung Naturstoff-Chemie, Jahnstr. 29, D-69 Heidelberg, F. R. G., and **Institut de Chimie Biologique, Unit& de Recherche sur le Cancer de I’INSERM et Centre de Neurochimie du C.N.R.S., FacultP de Midecine, F-67085 Strasbourg, France Received 9 February 1976 1. Introduction 2. Materials and methods The toxic cyclopeptides in Amanita phalloides All mushrooms of the Amanita species, except mushrooms weigh about 0.05% of the fresh tissue. A. rubescens and A. pantherina, were harvested near Two-thirds of this weight are phallotoxins, mostly the Trento (Italy) in 1974. The others were collected acidic compounds phallacidin and phallisacin [ 1,2] , near Heidelberg in 1975. The tissues (20-80 g) were the rest being amatoxins, predominantly cr-amanitin. homogenized in a Star mixer together with a two-fold A combination of chromatographic procedures [3] volume of methanol and then kept under stirring at permits the spectrophotometric determination of up 70°C for 1 h. After centrifugation the supernatant to 11 toxic compounds [4] in single mushrooms. The was evaporated in vacua. The residues were thoroughly sensitivity of this analysis is limited to 0.1 pg of each dried, washed with dry ether and dissolved in 2 ml of toxin, this being sufficient, however, to determine 5 water. The amatoxins were extracted from these different amatoxins in A.
    [Show full text]
  • The Effect of a High-Resolution Accurate Mass Spectrometer On
    GÜFBED/GUSTIJ (2020) 10 (4): 878-886 Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi DOI: 10.17714/gumusfenbil.680816 Araştırma Makalesi / Research Article The Effect of A High-Resolution Accurate Mass Spectrometer On Simultaneous Multiple Mushroom Toxin Detection Yüksek Çözünürlüklü Kütle Spektrometrenin Eşzamanlı Çoklu Mantar Toksin Tayinleri Üzerindeki Etkisi Yasemin NUMANOĞLU ÇEVİK*1,2,a 1MoH, Turkish Public Health General Directorate, Microbiology Reference Laboratory, Adnan Saygun Street 55, 06100 Sıhhıye, Ankara, TURKEY 2Separation Science Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 S4-Bis, 9000 Gent, Belgium • Geliş tarihi / Received: 29.01.2020 • Düzeltilerek geliş tarihi / Received in revised form: 17.06.2020 • Kabul tarihi / Accepted: 02.07.2020 Abstract Amatoxins are deadly wild mushroom toxins that cause severe poisoning in humans, from diarrhea to organ dysfunction. Mortality can be as high as 80% if no specific treatment is applied. In this study, separation and determination methods were developed for the simultaneous determination of 7 toxins belonging to Amanita phalloides. After extraction and purification of Amanita phalloides (death cap) wild mushrooms, toxins were detected using HPLC- ESI MS and exact mass with time of flight MS (TOF-MS) in positive ionization mode. In addition, it was observed that the toxins of α- and β-amanitine could be differentiated from each other thanks to HR-MS detection in case of their close retention (Rt) in LC. The presence of two toxins at the same retention point in the chromatogram was detected by differentiating the molecular ion mass (920.3514 DA) of the α-amanitine with the HR-MS (920.3696 DA).
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • Amanita Phalloides Poisoning: Mechanisms of Toxicity and Treatment
    Food and Chemical Toxicology 86 (2015) 41–55 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Review Amanita phalloides poisoning: Mechanisms of toxicity and treatment Juliana Garcia a,∗, Vera M. Costa a, Alexandra Carvalho b, Paula Baptista c,PaulaGuedesde Pinho a, Maria de Lourdes Bastos a, Félix Carvalho a,∗∗ a UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua José Viterbo Ferreiran° 228, 4050-313 Porto, Portugal b Department of Cell and Molecular Biology, Computational and Systems Biology, Uppsala University, Biomedical Center, Box 596, 751 24 Uppsala, Sweden c CIMO/School of Agriculture, Polytechnique Institute of Bragança, Campus de Santa Apolónia, Apartado 1172, 5301-854 Bragança, Portugal article info abstract Article history: Amanita phalloides, also known as ‘death cap’, is one of the most poisonous mushrooms, being involved Received 10 April 2015 in the majority of human fatal cases of mushroom poisoning worldwide. This species contains three main Received in revised form 8 September 2015 groups of toxins: amatoxins, phallotoxins, and virotoxins. From these, amatoxins, especially α-amanitin, Accepted 10 September 2015 are the main responsible for the toxic effects in humans. It is recognized that α-amanitin inhibits RNA Available online 12 September 2015 polymerase II, causing protein deficit and ultimately cell death, although other mechanisms are thought Keywords: to be involved. The liver is the main target organ of toxicity, but other organs are also affected, especially Amanita phalloides the kidneys. Intoxication symptoms usually appear after a latent period and may include gastrointestinal Amatoxins disorders followed by jaundice, seizures, and coma, culminating in death.
    [Show full text]
  • Protein-Polymer-Drug Conjugates
    (19) TZZ¥ ¥ _T (11) EP 3 228 325 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.10.2017 Bulletin 2017/41 A61K 47/59 (2017.01) A61K 47/68 (2017.01) A61K 47/64 (2017.01) A61P 35/00 (2006.01) (21) Application number: 17159707.3 (22) Date of filing: 11.06.2012 (84) Designated Contracting States: • THOMAS, Joshua D AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Natick, MA Massachusetts 01760 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAMMOND, Charles E PL PT RO RS SE SI SK SM TR Billerica, MA Massachusetts 01821 (US) • STEVENSON, Cheri A (30) Priority: 10.06.2011 US 201161495771 P Haverhill, MA Massachusetts 01832 (US) 24.06.2011 US 201161501000 P • BODYAK, Natalya D 29.07.2011 US 201161513234 P Boston, MA 02135 (US) 05.12.2011 US 201161566935 P • CONLON, Patrick R 01.03.2012 US 201261605618 P Wakefield, MA Massachusetts 01880 (US) 30.03.2012 US 201261618499 P • GUMEROV, Dmitry R Waltham, MA Massachusetts 02451 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Cooley (UK) LLP 12728014.7 / 2 717 916 Dashwood 69 Old Broad Street (71) Applicant: Mersana Therapeutics, Inc. London EC2M 1QS (GB) Cambridge, MA 02139 (US) Remarks: (72) Inventors: •Claims f iled aft er the date of fil ing of the • YURKOVETSKIY, Aleksandr application/after the date of receipt of the divisional Littleton, MA Massachusetts 01460 (US) application (Rule 68(4) EPC) • YIN, Mao •This application was filed on 07-03-2017 as a Needham, MA Massachusetts 02492 (US) divisional application to the application mentioned • LOWINGER, Timothy B under INID code 62.
    [Show full text]
  • | Hai Lala Mo at Alt a La La La Manual
    |HAI LALA MO ATUS009938323B2 ALT A LA LA LA MANUAL (12 ) United States Patent ( 10 ) Patent No. : US 9 ,938 , 323 B2 Grunewald et al. (45 ) Date of Patent : Apr . 10 , 2018 ( 54 ) AMATOXIN DERIVATIVES AND WO 2014135282 AL 9 / 2014 CONJUGATES THEREOF AS INHIBITORS WO 2014141094 Al 9 / 2014 OF RNA POLYMERASE WO 2016142049 AL 9 / 2016 (71 ) Applicant: NOVARTIS AG , Basel (CH ) OTHER PUBLICATIONS ( 72 ) Inventors : Jan Grunewald , San Diego , CA (US ) ; Yunho Jin , San Diego , CA (US ) ; Zhao , et al ., “ Synthesis of a Cytotoxic Amanitin for Biorthogonal Weijia Ou , San Diego , CA (US ) ; Conjugation ” , ChemBioChem , 2015 , pp . 1420 - 1425, vol . 16 , Tetsuo Uno , San Diego , CA (US ) Wiley - VCH Verlag GmbH & Co . Adair, et al ., “ Antibody -drug conjugates a perfect synergy ” , ( 73 ) Assignee : Novartis AG , Basel (CH ) Expert Opin . Biol. Ther. , 2012 , pp . 1191 - 1206 , vol. 12 , No . 9 , Informa UK , Ltd . ( * ) Notice : Subject to any disclaimer , the term of this Flygare , et al ., “ Antibody - Drug Conjugates for the Treatment of patent is extended or adjusted under 35 Cancer ” , Chem . Biol . Drug . Des. , 2013 , pp . 113 - 121 , vol. 81 , John Wiley & Sons A / S . U . S . C . 154 ( b ) by 0 days . Jackson , et al ., “ Using the Lessons Learned from the Clinic to Improve the Preclinical Development of Antibody Drug Conju (21 ) Appl. No. : 15 /524 , 197 gates ” , Pharm . Res . , 2014 , pp . 1 - 12 . (22 ) PCT Filed : Nov. 5 , 2015 (Continued ) ( 86 ) PCT No. : PCT/ IB2015 /058537 Primary Examiner — Jeanette Lieb $ 371 ( c ) ( 1 ) , ( 74 ) Attorney , Agent, or Firm — Daniel E . Raymond ; ( 2 ) Date : May 3, 2017 Genomics Institute of the Novartis Research Foundation ( 87) PCT Pub .
    [Show full text]